Albany Molecular Research, Inc. Opens New Facilities in Singapore and India
News Nov 02, 2005
Albany Molecular Research, Inc., has announced that its wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte. Ltd. (AMRSRC) has moved into permanent laboratory facilities in Singapore that provide room for significant growth.
Earlier this year, the company established AMRSRC in temporary facilities while the new laboratories were under construction. New facilities are now also operational in Hyderabad, India.
In Singapore, AMRI's new 16,000 square foot facility is located in Science Park III, near the Biopolis, a major biomedical research hub. The facility can currently accommodate over 50 scientists. Capabilities there include medicinal chemistry support, custom synthesis of building blocks and scaffolds, as well as non-GMP scale up.
AMRI has an additional 29,000 square feet of space in Singapore at this facility and currently plans to add laboratories for cGMP synthesis and analytical chemistry, as well as additional facilities for chemical synthesis.
The company also announced that it has opened its first laboratory in India. Albany Molecular Research Hyderabad Research Centre, Pvt. Ltd. (AMRHRC), a wholly owned subsidiary of the company, is located in the ICICI Knowledge Park near Hyderabad.
The newly constructed laboratory holds up to 12 scientists and is being used for custom synthesis of scaffolds and building blocks, as well as preparation of reference standards.
A second laboratory for preparing up to kilogram quantities of pharmaceutical intermediates, starting materials and other compounds is currently under construction and expected to be operational by early next year. Together, the two laboratories in India are anticipated to accommodate up to 30 scientists.
"The move into our permanent home in Singapore, and the opening of our first laboratory in India mark two more milestones in AMRI's history," said Chairman, CEO and President Thomas E. D'Ambra, Ph.D.
"Our worldwide chemistry services platform has enhanced our ability to provide customers with a flexible range of services and competitive cost models. Customer response to our flexible mix of global and U.S.-based resources has been overwhelmingly positive. As we approach 2006, we look forward to further expansions in Singapore and India and the continued success of our global chemistry platform."
AMRI's Singapore operations are being led by Polivina Jolicia F. Gauuan, Ph.D., who joined the company in 1995 after completing her Ph.D. in organic chemistry at the State University of New York at Albany. She relocated to Singapore, along with three other U.S.-based scientists, to form the site management team. AMRSRC currently has nineteen employees, including fifteen scientists.
"The support and encouragement we have received from the Singapore government and the Biomedical Sciences Group of the Economic Development Board has been vital to the success of our Phase I project," added D'Ambra. "I would like to take the opportunity to thank them for their efforts and congratulate them for their vision and forward thinking. Singapore has a business supportive culture."
AMRI's operations in India are led by Rajesh Shenoy, Ph.D., who joined AMRI in 1998. Dr. Shenoy earned his Ph.D. at the University of Akron and conducted postdoctoral research at Kent State University. He relocated to India, along with two other U.S.-based scientists, to form the site management team. AMRHRC currently has ten employees, including eight scientists.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE